within Pharmacolibrary.Drugs.ATC.B;

model B01AC23
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00011416666666666666,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007500000000000001,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0723,
    k12             = 27.7,
    k21             = 27.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AC23</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cilostazol is a phosphodiesterase III inhibitor used primarily as an antiplatelet and vasodilator agent to improve symptoms of intermittent claudication in patients with peripheral arterial disease. It is approved in multiple countries for this indication but has some restrictions due to cardiovascular risk.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Lim, TH, et al., &amp; Choi, DH (2015). Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats. <i>Journal of physiology and pharmacology : an official journal of the Polish Physiological Society</i> 66(4) 591–597. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26348083/\">https://pubmed.ncbi.nlm.nih.gov/26348083</a></p></li><li><p>Bramer, SL, et al., &amp; Mallikaarjun, S (1999). Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. <i>Clinical pharmacokinetics</i> 37 Suppl 2 1–11. DOI:<a href=\"https://doi.org/10.2165/00003088-199937002-00001\">10.2165/00003088-199937002-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10702882/\">https://pubmed.ncbi.nlm.nih.gov/10702882</a></p></li><li><p>Shin, KH, et al., &amp; Park, JW (2014). Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants. <i>The Journal of pharmacy and pharmacology</i> 66(7) 961–974. DOI:<a href=\"https://doi.org/10.1111/jphp.12227\">10.1111/jphp.12227</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24697278/\">https://pubmed.ncbi.nlm.nih.gov/24697278</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AC23;
